Connect with Us at the Upcoming Events

Creative Biolabs is excited to greet you at the upcoming international conferences. Meet our team at the 13th Annual World ADC San Diego and the 13th Annual World Multispecific Summit in September, the 10th Annual Immuno-Oncology Summit in October, and the Antibody Engineering & Therapeutics (US) 2022 in December for expert consultation on your drug discovery projects. Shoot an email to arrange an in-person meeting!

Book a Meeting

BetterBet™ Anti-HER2 On-Target Antibody (CAT#: AES-0622-ZP747) Datasheet

The development of On-Target Antibody is mainly to solve the problem of On-target toxicity in immunotherapy. For antibodies that activate the body's immune system, such as CTLA-4 and 4-1BB antibodies, they can systematically activate the body's immune system, resulting in excessive immune response. In addition, solid tumors are also expressev various targets which are also on the surface of normal cells, so antibodies can indiscriminately bind targets on tumor cells and targets on normal cells, resulting in side effects. On-Target Antibody takes advantage of the enrichment of some small molecules such as ATP in the tumor microenvironment, and activates the antibody by using the small molecule as a medium, so that the antibody is specifically activated only in the tumor.
"On-target" tumor antigen binding
ATP-mediated antibody engineering technology

Cooperation Seeking

Official Name
erb-b2 receptor tyrosine kinase 2
NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu

In the tumor microenvironment, ATP is released from necrotic, apoptotic and other tumor cells, so its concentration is higher than that of normal cells. On-Target Antibody takes advantage of the enrichment of ATP in the tumor microenvironment to activate the antibody with ATP as a medium, so that the antibody is specifically activated only in the tumor.

All products and services are for Research Use Only. Do Not use in humans.


Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *